Lisata Therapeutics, Inc. Common Stock (LSTA)
Lisata Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for musculoskeletal and degenerative conditions. The company leverages targeted delivery systems to enhance the efficacy of therapeutic agents, aiming to address unmet medical needs in chronic and age-related diseases.
Company News
Lisata Therapeutics and WARPNINE completed patient enrollment in a Phase 1b/2a trial evaluating certepetide for locally advanced pancreatic cancer, reporting promising preliminary data with a 60% overall response rate and 100% disease control rate.
Lisata Therapeutics' lead pipeline candidate, certepetide, has shown promising results in a preclinical study for treating intrahepatic cholangiocarcinoma, an aggressive form of cancer. The positive data underlines the potential of certepetide in improving the tumor environment and making tumors more responsive to immunotherapy.
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday. Applied Optoelectronics, Inc. (NASDAQ: AAOI) shares climbed 50.4% to settle at $3.76 on Friday after the company announced the sale of its Chinese manufacturing facilities to Yuhan Optoelectronic Technology for $150 million. iBio, Inc. (NYSE: IBIO) ...